Children's Hospital, Helsinki University Central Hospital, University of Helsinki, and Folkhälsan Research Center, P O Box 281, FIN-00029, Helsinki, Finland.
Nat Rev Rheumatol. 2013 Aug;9(8):465-75. doi: 10.1038/nrrheum.2013.45. Epub 2013 Apr 16.
Osteoporosis, a skeletal disorder characterized by compromised bone strength and an increased risk of fractures, is an important paediatric disorder that involves almost all paediatric subspecialties. Osteogenesis imperfecta is the most common form of childhood-onset primary osteoporosis, but several other forms are also known. Secondary osteoporosis is caused by an underlying chronic illness or its treatment. The most common causes of secondary osteoporosis include chronic systemic inflammation, glucocorticoid use and neuromuscular disabilities. The skeletal sequelae can present in childhood as low-energy peripheral and vertebral fractures, or become evident in adulthood as low bone mass and an increased propensity to develop osteoporosis. Management should aim at prevention, as interventions to treat symptomatic osteoporosis in the paediatric age group are scarce. Bisphosphonates are the principal pharmacological agents that can be used in this setting, but data on their efficacy and safety in paediatric populations remain inadequate, especially in patients with secondary osteoporosis. Consequently, it is important to understand the potential skeletal effects of paediatric illnesses and their therapies in order to institute effective and timely prevention of skeletal complications.
骨质疏松症是一种以骨强度受损和骨折风险增加为特征的骨骼疾病,是一种涉及几乎所有儿科亚专业的重要儿科疾病。成骨不全症是儿童期原发性骨质疏松症最常见的形式,但也有其他几种形式。继发性骨质疏松症是由潜在的慢性疾病或其治疗引起的。继发性骨质疏松症最常见的原因包括慢性全身炎症、糖皮质激素的使用和神经肌肉障碍。骨骼后遗症在儿童期表现为低能量外周和椎体骨折,或在成年期表现为低骨量和增加发生骨质疏松症的倾向。管理的目标应该是预防,因为在儿科年龄段治疗有症状的骨质疏松症的干预措施很少。双膦酸盐是可在此情况下使用的主要药物治疗剂,但关于其在儿科人群中的疗效和安全性的数据仍然不足,特别是在继发性骨质疏松症患者中。因此,了解儿科疾病及其治疗的潜在骨骼影响对于及时有效地预防骨骼并发症非常重要。